Your browser doesn't support javascript.
loading
Role of the repeat expansion size in predicting age of onset and severity in RFC1 disease.
Currò, Riccardo; Dominik, Natalia; Facchini, Stefano; Vegezzi, Elisa; Sullivan, Roisin; Galassi Deforie, Valentina; Fernández-Eulate, Gorka; Traschütz, Andreas; Rossi, Salvatore; Garibaldi, Matteo; Kwarciany, Mariusz; Taroni, Franco; Brusco, Alfredo; Good, Jean-Marc; Cavalcanti, Francesca; Hammans, Simon; Ravenscroft, Gianina; Roxburgh, Richard H; Parolin Schnekenberg, Ricardo; Rugginini, Bianca; Abati, Elena; Manini, Arianna; Quartesan, Ilaria; Ghia, Arianna; Lòpez de Munaìn, Adolfo; Manganelli, Fiore; Kennerson, Marina; Santorelli, Filippo Maria; Infante, Jon; Marques, Wilson; Jokela, Manu; Murphy, Sinéad M; Mandich, Paola; Fabrizi, Gian Maria; Briani, Chiara; Gosal, David; Pareyson, Davide; Ferrari, Alberto; Prados, Ferran; Yousry, Tarek; Khurana, Vikram; Kuo, Sheng-Han; Miller, James; Troakes, Claire; Jaunmuktane, Zane; Giunti, Paola; Hartmann, Annette; Basak, Nazli; Synofzik, Matthis; Stojkovic, Tanya.
Afiliación
  • Currò R; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
  • Dominik N; Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
  • Facchini S; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
  • Vegezzi E; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
  • Sullivan R; Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
  • Galassi Deforie V; IRCCS Mondino Foundation, 27100 Pavia, Italy.
  • Fernández-Eulate G; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
  • Traschütz A; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
  • Rossi S; Nord/Est/Ile-de-France Neuromuscular Reference Center, Institute of Myology, Pitié-Salpêtrière Hospital, APHP, 75013 Paris, France.
  • Garibaldi M; Research Division 'Translational Genomics of Neurodegenerative Diseases', Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, 72076 Tübingen, Germany.
  • Kwarciany M; German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, 72076 Tübingen, Germany.
  • Taroni F; Dipartimento di Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, UOC Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
  • Brusco A; Facoltà di Medicina e Chirurgia, Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Good JM; Neuromuscular and Rare Disease Center, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sant'Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy.
  • Cavalcanti F; Department of Adult Neurology, Medical University of Gdansk, 80-952 Gdansk, Poland.
  • Hammans S; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan 20133, Italy.
  • Ravenscroft G; Department of Medical Sciences, University of Torino, 10124 Turin, Italy.
  • Roxburgh RH; Division of Genetic Medicine, Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
  • Parolin Schnekenberg R; Wessex Neurological Centre, Southampton General Hospital, Southampton, SO16 6YD, UK.
  • Rugginini B; Neurogenetic Diseases Group, Centre for Medical Research, QEII Medical Centre, University of Western Australia, Nedland, WA 6009, Australia.
  • Abati E; Neurology Department, Auckland City Hospital, New Zealand and the Centre for Brain Research, University of Auckland, Auckland 1142, New Zealand.
  • Quartesan I; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
  • Ghia A; Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
  • Lòpez de Munaìn A; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
  • Manganelli F; Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.
  • Kennerson M; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
  • Santorelli FM; Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.
  • Infante J; Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
  • Marques W; Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
  • Jokela M; Neurology Department, Donostia University Hospital, University of the Basque Country-Osakidetza-CIBERNED-Biodonostia, 20014 Donostia-San Sebastián, Spain.
  • Murphy SM; Department of Neuroscience and Reproductive and Odontostomatological Sciences, University of Naples Federico II, 80131 Naples, Italy.
  • Mandich P; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2050, Australia.
  • Fabrizi GM; IRCCS Stella Maris Foundation, Molecular Medicine for Neurodegenerative and Neuromuscular Disease Unit, 56128 Pisa, Italy.
  • Briani C; University Hospital Marquès de Valdecilla-IDIVAL, University of Cantabria, 39008 Santander, Spain.
  • Gosal D; Department of Neurology, School of Medicine of Ribeirão Preto, University of São Paulo, 2650 Ribeirão Preto, Brazil.
  • Pareyson D; Neuromuscular Research Center, Department of Neurology, Tampere University and University Hospital, 33520 Tampere, Finland.
  • Ferrari A; Neurocenter, Department of Neurology, Clinical Neurosciences, Turku University Hospital and University of Turku, 20014 Turku, Finland.
  • Prados F; Department of Neurology, Tallaght University Hospital, D24 NR0A Dublin, Ireland.
  • Yousry T; Academic Unit of Neurology, Trinity College Dublin, D02 R590 Dublin, Ireland.
  • Khurana V; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, 16132 Genoa, Italy.
  • Kuo SH; IRCCS Ospedale Policlinico San Martino-UOC Genetica Medica, 16132 Genova, Italy.
  • Miller J; Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, 37134 Verona, Italy.
  • Troakes C; Department of Neurosciences, ERN Neuromuscular Unit, University of Padova, 35100 Padova, Italy.
  • Jaunmuktane Z; Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Greater Manchester, M6 8HD, UK.
  • Giunti P; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan 20133, Italy.
  • Hartmann A; IRCCS Mondino Foundation, 27100 Pavia, Italy.
  • Basak N; Centre for Medical Image Computing (CMIC), Department of Medical Physics and Biomedical Engineering, University College London, London, WC1V 6LJ, UK.
  • Synofzik M; NMR Research Unit, Institute of Neurology, University College London (UCL), London, WC1N 3BG, UK.
  • Stojkovic T; e-Health Centre, Universitat Oberta de Catalunya, 08018 Barcelona, Spain.
Brain ; 147(5): 1887-1898, 2024 May 03.
Article en En | MEDLINE | ID: mdl-38193360
ABSTRACT
RFC1 disease, caused by biallelic repeat expansion in RFC1, is clinically heterogeneous in terms of age of onset, disease progression and phenotype. We investigated the role of the repeat size in influencing clinical variables in RFC1 disease. We also assessed the presence and role of meiotic and somatic instability of the repeat. In this study, we identified 553 patients carrying biallelic RFC1 expansions and measured the repeat expansion size in 392 cases. Pearson's coefficient was calculated to assess the correlation between the repeat size and age at disease onset. A Cox model with robust cluster standard errors was adopted to describe the effect of repeat size on age at disease onset, on age at onset of each individual symptoms, and on disease progression. A quasi-Poisson regression model was used to analyse the relationship between phenotype and repeat size. We performed multivariate linear regression to assess the association of the repeat size with the degree of cerebellar atrophy. Meiotic stability was assessed by Southern blotting on first-degree relatives of 27 probands. Finally, somatic instability was investigated by optical genome mapping on cerebellar and frontal cortex and unaffected peripheral tissue from four post-mortem cases. A larger repeat size of both smaller and larger allele was associated with an earlier age at neurological onset [smaller allele hazard ratio (HR) = 2.06, P < 0.001; larger allele HR = 1.53, P < 0.001] and with a higher hazard of developing disabling symptoms, such as dysarthria or dysphagia (smaller allele HR = 3.40, P < 0.001; larger allele HR = 1.71, P = 0.002) or loss of independent walking (smaller allele HR = 2.78, P < 0.001; larger allele HR = 1.60; P < 0.001) earlier in disease course. Patients with more complex phenotypes carried larger expansions [smaller allele complex neuropathy rate ratio (RR) = 1.30, P = 0.003; cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS) RR = 1.34, P < 0.001; larger allele complex neuropathy RR = 1.33, P = 0.008; CANVAS RR = 1.31, P = 0.009]. Furthermore, larger repeat expansions in the smaller allele were associated with more pronounced cerebellar vermis atrophy (lobules I-V ß = -1.06, P < 0.001; lobules VI-VII ß = -0.34, P = 0.005). The repeat did not show significant instability during vertical transmission and across different tissues and brain regions. RFC1 repeat size, particularly of the smaller allele, is one of the determinants of variability in RFC1 disease and represents a key prognostic factor to predict disease onset, phenotype and severity. Assessing the repeat size is warranted as part of the diagnostic test for RFC1 expansion.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Edad de Inicio / Proteína de Replicación C Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Edad de Inicio / Proteína de Replicación C Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido